Lisata Therapeutics, Inc. - Common Stock LSTA 深 滬
等待開盤 09-06 09:30:00 美东时间
2.20
+0.090
+4.27%
華盛通- 最 高2.20
- 今 開2.08
- 成交量 8162股
- 最 低 2.07
- 昨 收 2.11
- 總市值 1891.60万
- 52周最高 4.20
- 市盈率 靜 --
- 換手率 0.09%
- 52周最低 1.87
- 委 比 42.86%
- 總股本 859.82万
- 歷史最高 1483.50
- 量 比 0.54
- 振 幅 6.16%
- 歷史最低 1.87
- 每 手 1
- 風險率 0.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Lisata Therapeutics announced that its CEO, David J. Mazzo, Ph.D., will provide a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference in New York City on September 8-10, 2025. The presentation will be available on-demand starting September 5, 2025, at 7:00 a.m. ET. Lisata, a clinical-stage pharmaceutical company, focuses on developing innovative therapies for advanced solid tumors. Its drug candidate, certepetide, a...
09-02 12:00
HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Lisata Therapeutics (NASDAQ:LSTA) with a Buy and maintains $15 price target.
08-21 19:18
Lisata Therapeutics Reports Strong Q2 2025 Financials
The latest announcement is out from Lisata Therapeutics ( ($LSTA) ). On August ...
08-08 04:43
Here are the major earnings after the close Thursday
Major earnings expected after the bell on Thursday include: Block (XYZ) Gilead Sciences (GILD) Twilio (TWLO) The Trade Desk (TTD) Main Street Capital Corporation (MAIN) Other earnings slated for rele...
08-07 22:00
Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Lisata Therapeutics reported a business update and Q2 2025 financial results. The company has a cash runway extending into Q4 2026 with no debt, funding current clinical programs through their next data milestones. Clinical trials include ASCEND, BOLSTER, and CENDIFOX, showing positive preliminary data for certepetide in treating solid tumors. Q2 revenue was $70K, down from Q2 2024 due to no revenue in the prior year. Operating expenses decreased...
08-07 20:05
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025
Lisata Therapeutics announced it will report its second-quarter 2025 financial results on August 7, 2025, followed by a conference call at 4:30 p.m. ET. Interested parties must register via the provided link to receive dial-in details. The call will also be webcast on the company's website and available for replay for 12 months. Lisata focuses on developing therapies for advanced solid tumors, with its candidate certepetide aiming to improve drug...
07-31 12:00
Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update
Lisata Therapeutics and WARPNINE announce the successful completion of patient enrollment in the Phase 1b/2a iLSTA trial evaluating certepetide in combination with standard-of-care chemotherapy and immunotherapy for locally advanced non-resectable pancreatic ductal adenocarcinoma (PDAC). The study, conducted at St John of God Subiaco Hospital, enrolled 30 participants across three treatment cohorts. Updated preliminary data presented at the 2025 ...
07-17 12:00
U.S. Patent And Trademark Office Issues Lisata Therapeutics Composition Of Matter Patent For Certepetide Through March 2040 With Opportunity For Patent Term Extension
Newly issued U.S. patent extends certepetide IP protection to 2040, with subsequent opportunity for patent term extensionThis patent covers novel cyclic peptides and their use in treating solid tumors
07-15 20:11
Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide
Lisata Therapeutics获得美国专利商标局颁发的新成分专利，有效期至2040年，涉及创新环状肽certepetide，用于治疗实体瘤。该专利加强了知识产权保护，防止仿制，并为公司未来商业化提供了支持。Certepetide通过激活特定运输系统，提高抗癌药渗入肿瘤的效果，已显示出良好临床疗效。
07-15 12:00
